Cargando…
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies
Many SARS-CoV-2-infected individuals remain asymptomatic. Little is known about the extent and quality of their antiviral humoral response. Here, we analyze antibody functions in 52 asymptomatic infected individuals, 119 mildly symptomatic, and 21 hospitalized patients with COVID-19. We measure anti...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057765/ https://www.ncbi.nlm.nih.gov/pubmed/33899033 http://dx.doi.org/10.1016/j.xcrm.2021.100275 |
_version_ | 1783680893496328192 |
---|---|
author | Dufloo, Jérémy Grzelak, Ludivine Staropoli, Isabelle Madec, Yoann Tondeur, Laura Anna, François Pelleau, Stéphane Wiedemann, Aurélie Planchais, Cyril Buchrieser, Julian Robinot, Rémy Ungeheuer, Marie-Noelle Mouquet, Hugo Charneau, Pierre White, Michael Lévy, Yves Hoen, Bruno Fontanet, Arnaud Schwartz, Olivier Bruel, Timothée |
author_facet | Dufloo, Jérémy Grzelak, Ludivine Staropoli, Isabelle Madec, Yoann Tondeur, Laura Anna, François Pelleau, Stéphane Wiedemann, Aurélie Planchais, Cyril Buchrieser, Julian Robinot, Rémy Ungeheuer, Marie-Noelle Mouquet, Hugo Charneau, Pierre White, Michael Lévy, Yves Hoen, Bruno Fontanet, Arnaud Schwartz, Olivier Bruel, Timothée |
author_sort | Dufloo, Jérémy |
collection | PubMed |
description | Many SARS-CoV-2-infected individuals remain asymptomatic. Little is known about the extent and quality of their antiviral humoral response. Here, we analyze antibody functions in 52 asymptomatic infected individuals, 119 mildly symptomatic, and 21 hospitalized patients with COVID-19. We measure anti-spike immunoglobulin G (IgG), IgA, and IgM levels with the S-Flow assay and map IgG-targeted epitopes with a Luminex assay. We also evaluate neutralization, complement deposition, and antibody-dependent cellular cytotoxicity (ADCC) using replication-competent SARS-CoV-2 or reporter cell systems. We show that COVID-19 sera mediate complement deposition and kill infected cells by ADCC. Sera from asymptomatic individuals neutralize the virus, activate ADCC, and trigger complement deposition. Antibody levels and functions are lower in asymptomatic individuals than they are in symptomatic cases. Antibody functions are correlated, regardless of disease severity. Longitudinal samplings show that antibody functions follow similar kinetics of induction and contraction. Overall, asymptomatic SARS-CoV-2 infection elicits polyfunctional antibodies neutralizing the virus and targeting infected cells. |
format | Online Article Text |
id | pubmed-8057765 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-80577652021-04-21 Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies Dufloo, Jérémy Grzelak, Ludivine Staropoli, Isabelle Madec, Yoann Tondeur, Laura Anna, François Pelleau, Stéphane Wiedemann, Aurélie Planchais, Cyril Buchrieser, Julian Robinot, Rémy Ungeheuer, Marie-Noelle Mouquet, Hugo Charneau, Pierre White, Michael Lévy, Yves Hoen, Bruno Fontanet, Arnaud Schwartz, Olivier Bruel, Timothée Cell Rep Med Article Many SARS-CoV-2-infected individuals remain asymptomatic. Little is known about the extent and quality of their antiviral humoral response. Here, we analyze antibody functions in 52 asymptomatic infected individuals, 119 mildly symptomatic, and 21 hospitalized patients with COVID-19. We measure anti-spike immunoglobulin G (IgG), IgA, and IgM levels with the S-Flow assay and map IgG-targeted epitopes with a Luminex assay. We also evaluate neutralization, complement deposition, and antibody-dependent cellular cytotoxicity (ADCC) using replication-competent SARS-CoV-2 or reporter cell systems. We show that COVID-19 sera mediate complement deposition and kill infected cells by ADCC. Sera from asymptomatic individuals neutralize the virus, activate ADCC, and trigger complement deposition. Antibody levels and functions are lower in asymptomatic individuals than they are in symptomatic cases. Antibody functions are correlated, regardless of disease severity. Longitudinal samplings show that antibody functions follow similar kinetics of induction and contraction. Overall, asymptomatic SARS-CoV-2 infection elicits polyfunctional antibodies neutralizing the virus and targeting infected cells. Elsevier 2021-04-20 /pmc/articles/PMC8057765/ /pubmed/33899033 http://dx.doi.org/10.1016/j.xcrm.2021.100275 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Dufloo, Jérémy Grzelak, Ludivine Staropoli, Isabelle Madec, Yoann Tondeur, Laura Anna, François Pelleau, Stéphane Wiedemann, Aurélie Planchais, Cyril Buchrieser, Julian Robinot, Rémy Ungeheuer, Marie-Noelle Mouquet, Hugo Charneau, Pierre White, Michael Lévy, Yves Hoen, Bruno Fontanet, Arnaud Schwartz, Olivier Bruel, Timothée Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies |
title | Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies |
title_full | Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies |
title_fullStr | Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies |
title_full_unstemmed | Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies |
title_short | Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies |
title_sort | asymptomatic and symptomatic sars-cov-2 infections elicit polyfunctional antibodies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057765/ https://www.ncbi.nlm.nih.gov/pubmed/33899033 http://dx.doi.org/10.1016/j.xcrm.2021.100275 |
work_keys_str_mv | AT dufloojeremy asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT grzelakludivine asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT staropoliisabelle asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT madecyoann asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT tondeurlaura asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT annafrancois asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT pelleaustephane asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT wiedemannaurelie asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT planchaiscyril asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT buchrieserjulian asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT robinotremy asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT ungeheuermarienoelle asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT mouquethugo asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT charneaupierre asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT whitemichael asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT levyyves asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT hoenbruno asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT fontanetarnaud asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT schwartzolivier asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies AT brueltimothee asymptomaticandsymptomaticsarscov2infectionselicitpolyfunctionalantibodies |